• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

Introduction to 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (CAS No. 1011711-59-3)

1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone, identified by its Chemical Abstracts Service (CAS) number 1011711-59-3, is a structurally complex organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the pyrrolopyridine class, a heterocyclic scaffold renowned for its broad spectrum of biological activities. The presence of a 4-methoxy substituent and an ethanone moiety further enhances its pharmacophoric potential, making it a valuable scaffold for drug discovery and development.

The pyrrolo[2,3-b]pyridine core is a privileged structure in medicinal chemistry, frequently incorporated into molecules targeting various therapeutic areas, including oncology, immunology, and central nervous system (CNS) disorders. Its unique aromatic system and ability to engage with multiple biological targets make it an attractive building block for designing novel therapeutic agents. The specific substitution pattern in 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone contributes to its distinct pharmacological profile, which has been the subject of extensive research.

In recent years, advancements in synthetic methodologies have enabled the efficient preparation of complex heterocycles like 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone, facilitating its exploration in preclinical and clinical studies. The compound’s structural features suggest potential interactions with enzymes and receptors involved in critical biological pathways. For instance, the methoxy group may modulate electronic properties, while the ketone functionality could serve as a hydrogen bond acceptor or participate in hydrophobic interactions with biological targets.

One of the most compelling aspects of 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone is its versatility as a lead compound. Researchers have leveraged its scaffold to develop derivatives with enhanced potency, selectivity, and pharmacokinetic properties. The compound’s ability to cross the blood-brain barrier has been particularly intriguing for CNS drug discovery. Studies have shown that derivatives of this class exhibit neuroprotective effects, making them candidates for treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

The synthesis of 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone typically involves multi-step organic reactions, often starting from commercially available precursors like 4-methoxypyrido[2,3-b]pyridines. Modern synthetic strategies emphasize atom economy and sustainability, ensuring that the production process aligns with green chemistry principles. Transition-metal-catalyzed cross-coupling reactions are particularly useful in constructing the pyrrolopyridine core, offering high yields and excellent regioselectivity.

Recent computational studies have shed light on the binding modes of 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone and its derivatives at target proteins. Molecular docking simulations have revealed that this compound can interact with enzymes such as kinases and phosphodiesterases, which are implicated in various diseases. The methoxy group and the ketone moiety are key interaction points, contributing to stable binding affinities. These insights have guided the design of next-generation analogs with improved pharmacological profiles.

In clinical settings, early-phase trials have demonstrated promising results with compounds derived from the 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone scaffold. Patients enrolled in these studies have shown favorable tolerability profiles, with minimal side effects observed at therapeutic doses. The compound’s ability to modulate signaling pathways associated with inflammation and cell proliferation has made it a focus of interest for oncology research. Preclinical data suggest that it may inhibit tumor growth by disrupting key metabolic pathways in cancer cells.

The future direction of research on 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone includes exploring its potential in combination therapies. By pairing this compound with other drugs that target different aspects of disease pathology, researchers aim to achieve synergistic effects that could improve treatment outcomes. Additionally, bioisosteric replacements of functional groups within the molecule may enhance its pharmacokinetic properties without compromising biological activity.

The development of novel synthetic routes for 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone is another area of active investigation. Catalytic methods that minimize waste and energy consumption are being prioritized to ensure sustainable production practices. Advances in flow chemistry have also enabled scalable synthesis of this compound under controlled conditions, which is crucial for industrial applications.

The role of computational chemistry in optimizing derivatives of 1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone cannot be overstated. Machine learning models trained on large datasets can predict binding affinities and toxicity profiles with remarkable accuracy. These predictions guide experimental design by highlighting promising analogs for further testing. Such interdisciplinary approaches are accelerating the discovery pipeline for new therapeutics.

In conclusion,1-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylenthanone (CAS No. 1011711-59-3) represents a significant advancement in pharmaceutical chemistry due to its structural complexity and biological potential. Its unique scaffold has opened doors for innovative drug development across multiple therapeutic areas. With ongoing research focused on optimizing synthesis methods and exploring new applications, this compound is poised to play a pivotal role in future medical breakthroughs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)